These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

293 related articles for article (PubMed ID: 22089931)

  • 21. Global gene expression profiling of PAX-FKHR fusion-positive alveolar and PAX-FKHR fusion-negative embryonal rhabdomyosarcomas.
    Laé M; Ahn EH; Mercado GE; Chuai S; Edgar M; Pawel BR; Olshen A; Barr FG; Ladanyi M
    J Pathol; 2007 Jun; 212(2):143-51. PubMed ID: 17471488
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Investigation of PAX3/7-FKHR fusion genes and IGF2 gene expression in rhabdomyosarcoma tumors.
    de Souza RR; Oliveira ID; Caran EM; Alves MT; Abib S; Toledo SR
    Growth Horm IGF Res; 2012 Dec; 22(6):245-9. PubMed ID: 23079386
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Examination of gene fusion status in archival samples of alveolar rhabdomyosarcoma entered on the Intergroup Rhabdomyosarcoma Study-III trial: a report from the Children's Oncology Group.
    Barr FG; Smith LM; Lynch JC; Strzelecki D; Parham DM; Qualman SJ; Breitfeld PP
    J Mol Diagn; 2006 May; 8(2):202-8. PubMed ID: 16645206
    [TBL] [Abstract][Full Text] [Related]  

  • 24. FOXO1-FGFR1 fusion and amplification in a solid variant of alveolar rhabdomyosarcoma.
    Liu J; Guzman MA; Pezanowski D; Patel D; Hauptman J; Keisling M; Hou SJ; Papenhausen PR; Pascasio JM; Punnett HH; Halligan GE; de Chadarévian JP
    Mod Pathol; 2011 Oct; 24(10):1327-35. PubMed ID: 21666686
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Genetic heterogeneity in the alveolar rhabdomyosarcoma subset without typical gene fusions.
    Barr FG; Qualman SJ; Macris MH; Melnyk N; Lawlor ER; Strzelecki DM; Triche TJ; Bridge JA; Sorensen PH
    Cancer Res; 2002 Aug; 62(16):4704-10. PubMed ID: 12183429
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Integrated genetic and epigenetic analysis defines novel molecular subgroups in rhabdomyosarcoma.
    Seki M; Nishimura R; Yoshida K; Shimamura T; Shiraishi Y; Sato Y; Kato M; Chiba K; Tanaka H; Hoshino N; Nagae G; Shiozawa Y; Okuno Y; Hosoi H; Tanaka Y; Okita H; Miyachi M; Souzaki R; Taguchi T; Koh K; Hanada R; Kato K; Nomura Y; Akiyama M; Oka A; Igarashi T; Miyano S; Aburatani H; Hayashi Y; Ogawa S; Takita J
    Nat Commun; 2015 Jul; 6():7557. PubMed ID: 26138366
    [TBL] [Abstract][Full Text] [Related]  

  • 27. PAX--FKHR fusion genes and AChR-gamma in Chinese patients with rhabdomyosarcoma: diagnosis using formalin-fixed archival tissues.
    Chang B; Pang LJ; Qi Y; Liu CX; Cao Y; Li HA; Hu WH; Jiang JF; Zhang WJ; Li F
    Int J Surg Pathol; 2009 Feb; 17(1):6-15. PubMed ID: 18988640
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Molecular Cytogenetics Detect an Unbalanced t(2;13)(q36;q14) and PAX3-FOXO1 Fusion in Rhabdomyosarcoma With Mixed Embryonal/Alveolar Features.
    La Starza R; Nofrini V; Pierini T; Pierini V; Zin A; Bisogno G; Cerri C; Caniglia M; Sidoni A; Ludwig K; Mecucci C
    Pediatr Blood Cancer; 2015 Dec; 62(12):2238-41. PubMed ID: 26179572
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Piperacetazine Directly Binds to the PAX3::FOXO1 Fusion Protein and Inhibits Its Transcriptional Activity.
    Nakazawa K; Shaw T; Song YK; Kouassi-Brou M; Molotkova A; Tiwari PB; Chou HC; Wen X; Wei JS; Deniz E; Toretsky JA; Keller C; Barr FG; Khan J; Üren A
    Cancer Res Commun; 2023 Oct; 3(10):2030-2043. PubMed ID: 37732905
    [TBL] [Abstract][Full Text] [Related]  

  • 30. PAX3-FOXO1 drives miR-486-5p and represses miR-221 contributing to pathogenesis of alveolar rhabdomyosarcoma.
    Hanna JA; Garcia MR; Lardennois A; Leavey PJ; Maglic D; Fagnan A; Go JC; Roach J; Wang YD; Finkelstein D; Hatley ME
    Oncogene; 2018 Apr; 37(15):1991-2007. PubMed ID: 29367756
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Divergent transcriptional and transforming properties of PAX3-FOXO1 and PAX7-FOXO1 paralogs.
    Manceau L; Richard Albert J; Lollini PL; Greenberg MVC; Gilardi-Hebenstreit P; Ribes V
    PLoS Genet; 2022 May; 18(5):e1009782. PubMed ID: 35604932
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Modeling of the human alveolar rhabdomyosarcoma Pax3-Foxo1 chromosome translocation in mouse myoblasts using CRISPR-Cas9 nuclease.
    Lagutina IV; Valentine V; Picchione F; Harwood F; Valentine MB; Villarejo-Balcells B; Carvajal JJ; Grosveld GC
    PLoS Genet; 2015; 11(2):e1004951. PubMed ID: 25659124
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Dense pattern of embryonal rhabdomyosarcoma, a lesion easily confused with alveolar rhabdomyosarcoma: a report from the Soft Tissue Sarcoma Committee of the Children's Oncology Group.
    Rudzinski ER; Teot LA; Anderson JR; Moore J; Bridge JA; Barr FG; Gastier-Foster JM; Skapek SX; Hawkins DS; Parham DM
    Am J Clin Pathol; 2013 Jul; 140(1):82-90. PubMed ID: 23765537
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Genomic and clinical analyses of 2p24 and 12q13-q14 amplification in alveolar rhabdomyosarcoma: a report from the Children's Oncology Group.
    Barr FG; Duan F; Smith LM; Gustafson D; Pitts M; Hammond S; Gastier-Foster JM
    Genes Chromosomes Cancer; 2009 Aug; 48(8):661-72. PubMed ID: 19422036
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Targeting KDM4 for treating PAX3-FOXO1-driven alveolar rhabdomyosarcoma.
    Singh S; Abu-Zaid A; Jin H; Fang J; Wu Q; Wang T; Feng H; Quarni W; Shao Y; Maxham L; Abdolvahabi A; Yun MK; Vaithiyalingam S; Tan H; Bowling J; Honnell V; Young B; Guo Y; Bajpai R; Pruett-Miller SM; Grosveld GC; Hatley M; Xu B; Fan Y; Wu G; Chen EY; Chen T; Lewis PW; Rankovic Z; Li Y; Murphy AJ; Easton J; Peng J; Chen X; Wang R; White SW; Davidoff AM; Yang J
    Sci Transl Med; 2022 Jul; 14(653):eabq2096. PubMed ID: 35857643
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Regulation of target genes of PAX3-FOXO1 in alveolar rhabdomyosarcoma.
    Ahn EH
    Anticancer Res; 2013 May; 33(5):2029-35. PubMed ID: 23645752
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Histology, Fusion Status, and Outcome in Alveolar Rhabdomyosarcoma With Low-Risk Clinical Features: A Report From the Children's Oncology Group.
    Arnold MA; Anderson JR; Gastier-Foster JM; Barr FG; Skapek SX; Hawkins DS; Raney RB; Parham DM; Teot LA; Rudzinski ER; Walterhouse DO
    Pediatr Blood Cancer; 2016 Apr; 63(4):634-9. PubMed ID: 26756883
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Validation of met as a therapeutic target in alveolar and embryonal rhabdomyosarcoma.
    Taulli R; Scuoppo C; Bersani F; Accornero P; Forni PE; Miretti S; Grinza A; Allegra P; Schmitt-Ney M; Crepaldi T; Ponzetto C
    Cancer Res; 2006 May; 66(9):4742-9. PubMed ID: 16651427
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Expression of fusion gene PAX3/PAX7-FKHR and chromosomal aberration in rhabdomyosarcoma].
    Gao H; Ou YL; Zhang KR; Zhang ZB; Wang WL
    Zhonghua Yi Xue Yi Chuan Xue Za Zhi; 2007 Feb; 24(1):42-7. PubMed ID: 17285543
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Survival outcomes of patients with localized FOXO1 fusion-positive rhabdomyosarcoma treated on recent clinical trials: A report from the Soft Tissue Sarcoma Committee of the Children's Oncology Group.
    Heske CM; Chi YY; Venkatramani R; Li M; Arnold MA; Dasgupta R; Hiniker SM; Hawkins DS; Mascarenhas L
    Cancer; 2021 Mar; 127(6):946-956. PubMed ID: 33216382
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.